Annexin Pharmaceuticals AB (OSTO:ANNX) ROCE %: -219.95% (As of Mar. 2026)


OSTO:ANNX Annexin Pharmaceuticals AB OSTO:ANNX
23 GF Score
Price kr12.50
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB ROCE %?

Annexin Pharmaceuticals AB OSTO:ANNX 23 ROCE % is -219.95% as of Mar. 2026. GuruFocus rates OSTO:ANNX with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Annexin Pharmaceuticals AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -219.95%.

Annexin Pharmaceuticals AB  (OSTO:ANNX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Annexin Pharmaceuticals AB ROCE % Related Terms

Annexin Pharmaceuticals AB ROCE % Historical Data

* Premium members only.

The historical data trend for Annexin Pharmaceuticals AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annexin Pharmaceuticals AB ROCE % Chart

Annexin Pharmaceuticals AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -149.29 -105.94 -179.87 -308.66 -190.93

Annexin Pharmaceuticals AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -112.72 -77.82 -99.56 -142.38 -219.95
OSTO:ANNX
23GF Score
Annexin Pharmaceuticals AB OSTO:ANNX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB ROCE % Calculation

Annexin Pharmaceuticals AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-36.893/( ( (19.036 - 5.323) + (30.156 - 5.224) )/ 2 )
=-36.893/( (13.713+24.932)/ 2 )
=-36.893/19.3225
=-190.93 %

Annexin Pharmaceuticals AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-43.272/( ( (30.156 - 5.224) + (19.978 - 5.563) )/ 2 )
=-43.272/( ( 24.932 + 14.415 )/ 2 )
=-43.272/19.6735
=-219.95 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -219.95% mean?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a ROCE % of -219.95% as of Mar. 2026.
Is Annexin Pharmaceuticals AB's ROCE % too high?
Annexin Pharmaceuticals AB's current ROCE % is -219.95%. Overall, Annexin Pharmaceuticals AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Annexin Pharmaceuticals AB's ROCE % compare to VRTX and REGN?
Annexin Pharmaceuticals AB's ROCE % of -219.95% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Annexin Pharmaceuticals AB's current ROCE % is -219.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexin Pharmaceuticals AB stock overvalued right now?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a current ROCE % of -219.95%. The current ROCE % is -219.95%. Annexin Pharmaceuticals AB's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Annexin Pharmaceuticals AB (OSTO:ANNX), the current ROCE % is -219.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annexin Pharmaceuticals AB Business Description

Other Exchanges Q910:Germany
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
23GF Score

Get the complete analysis for OSTO:ANNX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.50
Price